ArticleDiabetology & metabolic syndrome2026
The role of hepatocyte growth factor in the relationship between body fat distribution and plasma markers of glucose metabolism: a cross-sectional study.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity, particularly central adiposity, is a major risk factor for impaired glucose metabolism and type 2 diabetes. The biological mechanisms linking body fat distribution to glucose regulation remain incompletely understood. Therefore, we investigated the associations between body fat distribution and plasma markers of glucose metabolism in a population-based sample and examined the mediating role of hepatocyte growth factor (HGF) in this connection.
methodsThe analysis was based on data from 238 participants of the MEGA study (German acronym for metabolic health study Augsburg) conducted between 2018 and 2021. Anthropometric measurements and a body composition analysis via bioelectrical impedance analysis (BIA) were conducted. HGF was measured from EDTA plasma based on the Proximity Extension Assay (Olink inflammation panel). Multivariable linear regression models were chosen to examine the associations between standardized anthropometric and BIA measurements and the outcome variables in non-diabetic individuals. Obesity measures included body mass index (BMI), waist circumference (WC), visceral adipose tissue (VAT), and waist-to-hip ratio (WHR), relative fat mass (RFMV), and absolute fat mass (AFMV). The outcome variables included fasting glucose, two-hour OGTT glucose, and HbA1c concentrations. Mediation effects of HGF between obesity measures and glucose parameters were assessed.
resultsThe observed positive associations between obesity measures and glucose metabolism were stronger for variables that are indicative of central obesity (WC, WHR, VAT), when compared to indices of general obesity (BMI, RFMV, AFMV). Fasting glucose showed the strongest positive association with WC (β = 5.10 mg/dL per one standard deviation increase; 95% CI 1.86-5.77). For two-hour plasma glucose, the strongest associations were observed with WHR (β = 21.00; 95% CI 14.57-27.44). HGF mediated between 7.0% and 9.1% of the total effects with two-hour glucose levels but not the associations with the other outcomes. No associations were found with HbA1c levels after accounting for multiple testing.
conclusionsThese findings suggest HGF may contribute to the metabolic effects of different obesity measures on post-load glucose regulation, providing insights into obesity-related glucose dysregulation and potential targets for early intervention. However, the causal role of HGF remains unproven; further studies on the exact pathophysiological mechanisms are necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.